# US 2003/0203378 A1 · Methods to screen for antibiotic agents and their use in treatment of opportunistic infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203378 A1
- Document ID: US20030203378A1
- Status: Published application
- Kind: A1
- Application number: 10/320,210
- Filed: 2002-12-16
- Published: 2003-10-30
- Earliest claimed: 2000-06-30
- Assignees: Brown University Research Foundation
- Inventors: Susan Gerbi; Thilo Sascha Lange; Anton Borovjagin
- Web page: https://patentgrep.com/patent/US20030203378A1

## CPC

- C12Q 1/18: Testing for antimicrobial activity of a material
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel targets in eukaryotic cells for antibiotic agents and methods for identification of antibiotic agents affecting such targets and the use of the identified antibiotic agents in treatment of opportunistic infections in eukaryotic hosts. The invention is based upon the identification of species specific 5′ hinge and 3′ hinge regions of U3 small nucleolar ribonucleic acid (snoRNA). The present invention discloses that the external transcribed spacer (ETS) of the ribosomal RNA precursor (pre-rRNA) comprises sequences that are complementary to the 5′ and 3′ hinge regions of U3 snoRNA. The invention further discloses that sequence substitutions of the 5′ hinge or 3′ hinge region of U3 snoRNA severely compromise or fully inhibit the cleavage events at sites 1 and 2 in rRNA processing necessary to form mature 18S rRNA which is a vital component of the small subunit of ribosomes of all eukaryotes.

## Claims

### Claim 1

A method of screening for an antibiotic agent comprising the steps of
(a) providing a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow binding of said first and second recombinant RNAs; and
(b) contacting said mixture with a candidate antibiotic agent under conditions which permit inhibition of said binding wherein inhibition of said binding is indicative of an antibiotic agent.

### Claim 2

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow processing of said second recombinant ribonucleic acid; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of processing of said second recombinant RNA wherein said inhibition of processing is indicative of the antibiotic agent.

### Claim 3 (depends on 2)

The method of claim 2 wherein the cell is an eukaryotic cell.

### Claim 4 (depends on 2)

The method of claim 2 wherein the cell grows as a single cell.

### Claim 5 (depends on 2)

The method of claim 2 wherein the cell is a yeast cell.

### Claim 6 (depends on 2)

The method of claim 2 wherein the cell is a Xenopus oocyte.

### Claim 7

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 3′ and 5′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow ribosome synthesis; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of said ribosome synthesis wherein said inhibition of ribosome synthesis is indicative of the antibiotic agent.

### Claim 8 (depends on 7)

The method of claim 7 wherein the cell is an eukaryotic cell.

### Claim 9 (depends on 7)

The method of claim 7 wherein the cell grows as a single cell.

### Claim 10 (depends on 7)

The method of claim 7 wherein the cell is a yeast cell.

### Claim 11 (depends on 7)

The method of claim 7 wherein the cell is a Xenopus oocyte.

### Claim 12

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow protein synthesis; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of protein synthesis wherein said inhibition of protein synthesis is indicative of the antibiotic agent.

### Claim 13 (depends on 12)

The method of claim 12 wherein the cell is an eukaryotic cell.

### Claim 14 (depends on 12)

The method of claim 12 wherein the cell grows as a single cell.

### Claim 15 (depends on 12)

The method of claim 12 wherein the cell is a yeast cell.

### Claim 16

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow growth of said cell; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of growth of said cell wherein said inhibition of inhibition of growth is indicative of the antibiotic agent.

### Claim 17 (depends on 16)

The method of claim 16 wherein the cell, is an eukaryotic cell.

### Claim 18 (depends on 16)

The method of claim 16 wherein the cell grows as a single cell.

### Claim 19 (depends on 16)

The method of claim 16 wherein the cell is a yeast cell.

### Claim 20

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow division of said cell and thereby increase in the cell number; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of said cell division wherein said inhibition of cell division is indicative of the antibiotic agent.

### Claim 21 (depends on 20)

The method of claim 20 wherein the cell is an eukaryotic cell.

### Claim 22 (depends on 20)

The method of claim 20 wherein the cell grows as a single cell.

### Claim 23 (depends on 20)

The method of claim 20 wherein the cell is a yeast cell.

### Claim 24

A method of screening for an antibiotic agent comprising the steps of
(a) providing in a living cell a mixture of a first recombinant RNA comprising 5′ and 3′ hinge regions of domain I of U3 snoRNA and a second recombinant RNA comprising pre-rRNA under conditions that allow said cell to live; and
(b) contacting said cell with a candidate antibiotic agent under conditions which permit inhibition of cell viability wherein said inhibition of cell viability is indicative of the antibiotic agent.

### Claim 25 (depends on 24)

The method of claim 24 wherein the cell is an eukaryotic cell.

### Claim 26 (depends on 24)

The method of claim 24 wherein the cell grows as a single cell.

### Claim 27 (depends on 24)

The method of claim 24 wherein the cell is a yeast cell.

### Claim 28

A method of inhibiting cell growth comprising contacting the cell with an antibiotic agent under conditions which permit inhibition of pre-rRNA processing wherein said inhibition of processing inhibits cell growth.

### Claim 29

A method of inhibiting cell growth comprising contacting the cell with an antibiotic agent that inhibits synthesis of the ribosome under conditions which permit inhibition of synthesis of the ribosome wherein said inhibition of synthesis of the ribosome inhibits cell growth.

### Claim 30

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a pathogen in an amount sufficient to reduce or prevent said opportunistic infection wherein said antibiotic agent inhibits processing of pre-rRNA of said pathogen.

### Claim 31

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a eukaryotic pathogen in an amount sufficient to reduce or prevent said opportunistic infection, and wherein said antibiotic agent inhibits protein synthesis of said pathogen.

### Claim 32

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a eukaryotic pathogen in an amount sufficient to reduce or prevent said opportunistic infection wherein said antibiotic agent inhibits cell growth of said pathogen.

### Claim 33

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a eukaryotic pathogen in an amount agent sufficient to reduce or prevent said opportunistic infection wherein said antibiotic inhibits cell division of said pathogen thereby inhibiting the increase of the cell number of said pathogen.

### Claim 34

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a eukaryotic pathogen in an amount sufficient to reduce or prevent said opportunistic infection, wherein said antibiotic agent inhibits synthesis of the ribosome, and wherein said antibiotic agent inhibits protein synthesis by said pathogen.

### Claim 35

A method of treating an opportunistic infection comprising administering an antibiotic agent to a eukaryotic host suspect of or infected by a eukaryotic pathogen in an amount sufficient to reduce or prevent said opportunistic infection, wherein said antibiotic agent promotes cell death of said pathogen.

### Claim 36

A method of inhibiting cell growth comprising contacting the cell with an antibiotic agent that wherein said antibiotic agent has the capacity to inhibit binding between a recombinant RNA comprising 5′ and 3′ hinge regions of U3 snoRNA and an RNA comprising pre-rRNA under conditions which permit inhibition of protein synthesis wherein said inhibition of protein synthesis inhibits cell growth.

### Claim 37 (depends on 29)

The method of claim 29 wherein said agent inhibits synthesis of the 18S ribosomal subunit RNA.
